Werba Rubin Papier Wealth Management Sells 893 Shares of Novo Nordisk A/S (NYSE:NVO)

Werba Rubin Papier Wealth Management cut its stake in Novo Nordisk A/S (NYSE:NVO) by 16.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,570 shares of the company’s stock after selling 893 shares during the quarter. Werba Rubin Papier Wealth Management’s holdings in Novo Nordisk A/S were worth $393,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Natixis Advisors LLC grew its stake in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC grew its position in Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares during the period. Versant Capital Management Inc bought a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $86,000. Talbot Financial LLC bought a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $4,066,000. Finally, Clear Creek Financial Management LLC bought a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $450,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Up 5.9 %

Shares of Novo Nordisk A/S stock opened at $82.44 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The firm’s 50-day moving average is $87.45 and its two-hundred day moving average is $108.84. The stock has a market cap of $369.97 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 0.84 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 21.88%.

Analysts Set New Price Targets

Several brokerages recently issued reports on NVO. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.